Bulk Inquiry
Erlotinib hydrochloride
- OSI 774
- Parent CAS: 183321-74-6
- Soluble in DMSO
- MF: C22H23N3O4.HCl
- MW: 429.9
Description
Erlotinib hydrochloride (OSI 774) is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. It inhibits EGFR tyrosine kinase autophosphorylation by targeting the intracellular kinase domain and shows higher potency toward EGFR than toward c-Src or v-Abl in reported assays.
EGFR signaling regulates proliferation, survival, differentiation and oncogenic growth. Erlotinib hydrochloride is a widely used reference inhibitor for EGFR pathway research, receptor tyrosine kinase pharmacology and cancer cell signaling studies.
Key Features
- EGFR tyrosine kinase inhibitor
- Inhibits EGFR autophosphorylation
- Targets the intracellular kinase domain
- Reference compound for EGFR pathway studies
Applications
- EGFR signaling research
- Cancer cell proliferation and survival assays
- Receptor tyrosine kinase inhibitor profiling
- MAPK/PI3K pathway studies
More Information
| Parent CAS No. | 183321-74-6 |
|---|---|
| Chemical Name | [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine hydrochloride |
| SMILES | C1(OCCOC)C=C2C(NC3C=CC=C(C#C)C=3)=NC=NC2=CC=1OCCOC.Cl |
| MFCD | MFCD07781272 |
| InChi | InChI=1S/C22H23N3O4.ClH/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22;/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25);1H |
| InChiKey | GTTBEUCJPZQMDZ-UHFFFAOYSA-N |
| CID | 176871 |
| Short Description | EGFR inhibitor |
References
- J.R. Johnson et al. Approval Summary for Erlotinib for Treatment of Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer after Failure of at Least One Prior Chemotherapy Regimen. Clin. Can. Res. 2005, 11, 6414-6421.
- J. Porter et al. A dose escalation and pharmacokinetic (PK) trial of weekly docetaxel combined with daily erlotinib in adult cancer patients. J. Clin. Oncol.2004, 22, 14S, 2119.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1393 | Gefitinib |
From $77.00 |
| 1395 | Lapatinib ditosylate |
From $88.00 |
| 1398 | Sunitinib malate |
From $88.00 |
| 1411 | Vandetanib |
From $55.00 |
| 1414 | AG 013736 |
From $55.00 |
| 1420 | Pazopanib hydrochloride |
From $66.00 |
| 1433 | CI 1033 |
From $66.00 |
| 1461 | Cediranib |
From $77.00 |
| 1506 | WZ 4002 |
From $77.00 |
| 1526 | Neratinib |
From $88.00 |
| 1544 | BIBW 2992 |
From $55.00 |
| 1547 | OSI 930 |
From $99.00 |
| 1632 | OSI 420 |
From $99.00 |
| 1637 | Vatalanib |
From $82.50 |
| 1638 | ABT 869 |
From $88.00 |
| 1653 | AEE 788 |
From $88.00 |
| 1662 | CP 547632 |
From $77.00 |
| 1665 | Pelitinib |
From $99.00 |
| 1667 | SU 5402 |
From $66.00 |
| 1678 | Regorafenib |
From $77.00 |
| 1717 | Tivozanib |
From $88.00 |
| 1760 | EGFR Inhibitor [879127-07-8] |
From $132.00 |
| 1768 | AMG 706 |
From $115.50 |
| 1819 | Cabozantinib S-malate |
From $66.00 |
